SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
SVLSF IV, LLC

(Last) (First) (Middle)
60 STATE STREET, SUITE 3650

(Street)
BOSTON MA 02109

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeurogesX Inc [ NGSX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
05/03/2010
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 05/03/2010 S 291,718 D $10.25 2,159,991 D
Common Stock(2) 05/03/2010 S 8,282 D $10.25 61,324 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
SVLSF IV, LLC

(Last) (First) (Middle)
60 STATE STREET, SUITE 3650

(Street)
BOSTON MA 02109

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SV LIFE SCIENCES FUND IV LP

(Last) (First) (Middle)
60 STATE STREET, SUITE 3650

(Street)
BOSTON MA 02109

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS L P

(Last) (First) (Middle)
60 STATE STREET, SUITE 3650

(Street)
BOSTON MA 02109

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SV Life Sciences Fund IV (GP), L.P.

(Last) (First) (Middle)
60 STATE STREET, SUITE 3650

(Street)
BOSTON MA 02109

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. These shares were sold by SV Life Sciences Fund IV, L.P. ("SVLS IV LP"). SV Life Sciences Fund IV (GP), L.P. ("SVLS IV GP"), the general partner of SVLS IV LP, may be deemed to have voting and dispositive power over the securities held by SVLS IV LP. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to have voting and dispositive power over the securities held by SVLS IV LP. Each of SVLS IV GP and SVLSF IV, LLC disclaims beneficial ownership of securities held by SVLS IV LP except to the extent of any pecuniary interest therein. SVLS IV LP and SV Life Sciences Fund IV Strategic Partners, L.P. ("Strategic Partners") (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the securities held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of securities held by any other Fund except to the extent of any pecuniary interest therein.
2. These shares were sold by Strategic Partners. SVLS IV GP, the general partner of Strategic Partners, may be deemed to have voting and dispositive power over the securities held by Strategic Partners. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to have voting and dispositive power over the securities held by Strategic Partners. Each of SVLS IV GP and SVLSF IV, LLC disclaims beneficial ownership of securities held by Strategic Partners except to the extent of any pecuniary interest therein. Each Fund may be deemed to beneficially own the securities held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of securities held by any other Fund except to the extent of any pecuniary interest therein.
/s/ Denise Marks, an Authorized Signatory 05/05/2010
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.